Related Experiment Video
Updated: Jan 26, 2026

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
Published on: August 11, 2011
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced
Salah-Eddine Bentebibel1, Michael E Hurwitz2, Chantale Bernatchez1
1The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
NKTR-214 (bempegaldesleukin) is a novel IL2 pathway agonist, designed to provide sustained signaling through heterodimeric IL2 receptor βγ to drive increased proliferation and activation of CD8+ T and natural killer cells without unwanted expansion of T regulatory cells (Treg) in the tumor microenvironment. In this first-in-human multicenter phase I study, NKTR-214 administered as an outpatient regimen was well tolerated and showed clinical activity including tumor shrinkage and durable disease stabilization in heavily pretreated patients. Immune activation and increased numbers of immune cells were observed in the periphery across all doses and cycles with no loss of NKTR-214 activity with repeated administration. On-treatment tumor biopsies demonstrated that NKTR-214 promoted immune cell increase with limited increase of Tregs. Transcriptional analysis of tumor biopsies showed that NKTR-214 engaged the IL2 receptor pathway and significantly increased genes associated with an effector phenotype. Based on safety and pharmacodynamic markers, the recommended phase II dose was determined to be 0.006 mg/kg every three weeks. SIGNIFICANCE: We believe that IL2- and IL2 pathway-targeted agents such as NKTR-214 are key components to an optimal immunotherapy treatment algorithm. Based on its biological activity and tolerability, NKTR-214 is being studied with approved immuno-oncology agents including checkpoint inhibitors.See related commentary by Sullivan, p. 694.This article is highlighted in the In This Issue feature, p. 681.
Insights
NKTR-214 (bempegaldesleukin), an IL2 pathway agonist, demonstrated safety and clinical activity in a phase I study. It effectively activated immune cells and reduced tumors without expanding regulatory T cells.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- NKTR-214 (bempegaldesleukin) is a novel IL2 pathway agonist engineered for sustained IL2 receptor signaling.
- It aims to enhance CD8+ T and natural killer cell activation while minimizing regulatory T cell (Treg) expansion in the tumor microenvironment.
Purpose of the Study:
- To evaluate the safety, tolerability, and preliminary clinical activity of NKTR-214 in a first-in-human phase I study.
- To determine the recommended Phase II dose (RP2D) for NKTR-214.
Main Methods:
- A multicenter, first-in-human, phase I study of NKTR-214 administered in an outpatient setting.
- Assessment of safety, pharmacodynamics (immune cell activation, Treg levels), and clinical activity (tumor response, disease stabilization) through peripheral blood analysis and on-treatment tumor biopsies.
- Transcriptional analysis of tumor biopsies to evaluate IL2 pathway engagement and effector gene expression.
Main Results:
- NKTR-214 was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization in heavily pretreated patients.
- Observed immune activation and increased immune cell numbers in peripheral blood across all doses, with sustained activity upon repeated administration.
- On-treatment biopsies confirmed NKTR-214 promoted immune cell increases with limited Treg expansion, and transcriptional analysis indicated IL2 pathway engagement and increased effector gene expression.
Conclusions:
- NKTR-214 is a well-tolerated IL2 pathway agonist with demonstrated clinical activity and favorable immunomodulatory effects.
- The recommended Phase II dose of NKTR-214 is 0.006 mg/kg every three weeks.
- NKTR-214 shows promise as a key component in immunotherapy treatment algorithms, particularly in combination with agents like checkpoint inhibitors.
Related Concept Videos
Bias in Epidemiological Studies
Confirmation Biases
Hindsight Biases
Bias
In statistics, a sampling bias is created when a sample is collected from a population, and some members of the population are not as likely to be chosen as others (remember, each member...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...

